From our meta-analysis, in NSCLC individuals, age group, smoking status, liver metastasis status, EGFR mutation status, race, as well as expression of PD-L1 can predict the potency of atezolizumab in individuals aged <65 years old and 65–74 years old, active or previous smokers, those without liver metastasis, those with EGFR wild-type, white individuals, and those with TC3 or IC3, TC2/3 or IC2/3, TC1/2/3 or IC1/2/3, as well as TC0 and IC0, all of whom may benefit from atezolizumab treatment. This evidence concerns the gene EGFR and non-small cell lung carcinoma.